Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
glycopeptide antibiotic |
| gptkbp:activeIn |
gptkb:Streptococcus_pyogenes
gptkb:methicillin-resistant_Staphylococcus_aureus_(MRSA) Enterococcus faecalis (vancomycin-susceptible strains) |
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J01XA03
|
| gptkbp:brand |
Vibativ
|
| gptkbp:CASNumber |
372151-71-8
|
| gptkbp:contraindication |
hypersensitivity to telavancin
|
| gptkbp:developedBy |
Theravance
|
| gptkbp:drugClass |
lipoglycopeptide
|
| gptkbp:eliminationHalfLife |
7-9 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasBoxedWarning |
nephrotoxicity
fetal risk increased mortality in patients with pre-existing moderate/severe renal impairment |
| gptkbp:hasMolecularFormula |
C80H106Cl2N11O27P
|
| https://www.w3.org/2000/01/rdf-schema#label |
telavancin
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
disrupts bacterial cell membrane potential |
| gptkbp:metabolism |
not significantly metabolized
|
| gptkbp:molecularWeight |
1756.7 g/mol
|
| gptkbp:notEffectiveAgainst |
Gram-negative bacteria
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
CHEMBL1201832
16124629 17232813 DB06402 |
| gptkbp:riskFactor |
QT prolongation
nephrotoxicity |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting taste disturbance kidney dysfunction foamy urine |
| gptkbp:status |
approved in US
not approved in EU |
| gptkbp:target |
Gram-positive bacteria
|
| gptkbp:UNII |
3O2K93GZ5H
|
| gptkbp:usedFor |
treatment of ventilator-associated bacterial pneumonia
treatment of hospital-acquired bacterial pneumonia treatment of complicated skin and skin structure infections |
| gptkbp:bfsParent |
gptkb:Glycopeptides
|
| gptkbp:bfsLayer |
5
|